ArriVent BioPharma, Inc. Common Stock (AVBP) Stock
Fundamentals
Recent news

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
AVBP

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
AVBP

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
AVBP

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
AVBP
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 5 articles
published over the past 14 days
Latest news

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
AVBP

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
AVBP

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
AVBP

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
AVBP

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
AVBP
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President & CEO | 1966 |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research & Development and Director | 1961 |
| Mr. Winston Kung M.B.A. | CFO & Treasurer | 1976 |
| Ms. Robin LaChapelle M.A. | Co-Founder & COO | 1973 |
| Ms. Yang Wang Ph.D. | Chief Technology Officer | — |
| Dr. James Paul Kastenmayer J.D., Ph.D. | General Counsel & Secretary | 1972 |
| Mr. Brent S. Rice | Chief Commercial Officer | 1966 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
4 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.5 | -0.5 | +28.4 | +0.9 | +13.2 | -13.6 | +1.4 | -5.6 |



